Advertisement

Definition and Concept of Vascular Cognitive Impairment

  • Fernando D. TestaiEmail author
  • Philip B. Gorelick
Chapter
  • 27 Downloads
Part of the Stroke Revisited book series (STROREV)

Abstract

Worldwide, it is estimated that approximately 35 million people had dementia in 2010. With the prevalence of this condition expected to double every 20 years, dementia remains an important public health challenge. These estimates along with the growing costs of contemporary medical care have heightened interest in this disabling and progressive condition. Alzheimer disease and vascular cognitive impairment account for almost 70% of all the dementias. These two entities were traditionally considered divergent disorders. However, autopsy studies and data obtained using state-of-the-art neuroimaging modalities demonstrate that these dementia subtypes commonly coexist in the elderly. There is substantial observational epidemiologic evidence that links vascular risk factors in midlife to Alzheimer disease in the elderly. In addition, neurodegeneration and atherosclerosis have a synergistic effect on cognitive decline. These observations have fueled the provocative idea that a substantial number of the dementia cases can be prevented by controlling traditional vascular risk factors. In this chapter, we review the epidemiology and the evolution of diagnostic criteria for dementia with special emphasis on vascular cognitive impairment. In addition, we discuss the contribution of vascular risk factors to neurodegeneration and novel strategies to prevent or delay cognitive decline.

References

  1. 1.
    World Health Organization and Alzheimer’s Disease International. Dementia: a public health priority. Report of the World Health Organization. 2012. http://apps.who.int/iris/bitstream/10665/75263/1/9789241564458_eng.pdf?ua=1. Accessed 20 Sep 2017.
  2. 2.
    Prince M, Comas-Herrera A, Knapp M, Guerchet M. et al. World Alzheimer Report 2016. The Global Impact of Dementia. An analysis of prevalence, incidence, cost and trends. 2017. https://www.alz.co.uk/research/WorldAlzheimerReport2016.pdf. Accessed 20 Sep 2017.
  3. 3.
    Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement. 2016;12(4):459–509.CrossRefGoogle Scholar
  4. 4.
    Roth DL, Fredman L, Haley WE. Informal caregiving and its impact on health: a reappraisal from population-based studies. Gerontologist. 2015;55(2):309–19.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Gorelick PB, Mangone CA. Vascular dementias in the elderly. Clin Geriatr Med. 1991;7(3):599–615.PubMedCrossRefGoogle Scholar
  6. 6.
    Roth M. The natural history of mental disorder in old age. J Ment Sci. 1955;101(423):281–301.PubMedCrossRefGoogle Scholar
  7. 7.
    Mayer-Gross W, Slater E, Roth M. Clinical psychiatry. In: Anonymous. 3rd ed. Baltimore: Williams and Wilkins; 1969. p. 593–69.Google Scholar
  8. 8.
    Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet. 1974;2(7874):207–10.PubMedCrossRefGoogle Scholar
  9. 9.
    Hachinski VC. The decline and resurgence of vascular dementia. CMAJ. 1990;142(2):107–11.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Pantoni L, Gorelick PB, editors. Cerebral small vessel disease. Cambridge: Cambridge University Press; 2014.Google Scholar
  11. 11.
    Hachinski V, Sposato LA. Dementia: from muddled diagnoses to treatable mechanisms. Brain. 2013;136(Pt 9):2652–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250–60.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Farooq MU, Min J, Goshgarian C, et al. Pharmacotherapy for vascular cognitive impairment. CNS Drugs. 2017;31(9):759–76.PubMedCrossRefGoogle Scholar
  14. 14.
    Chui HC, Victoroff JI, Margolin D, et al. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology. 1992;42(3 Pt 1):473–80.PubMedCrossRefGoogle Scholar
  15. 15.
    Rosenberg GA, Wallin A, Wardlaw JM, et al. Consensus statement for diagnosis of subcortical small vessel disease. J Cereb Blood Flow Metab. 2016;36(1):6–25.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672–713.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Sachdev P, Kalaria R, O’Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206–18.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    American Psychiatric Association, editor. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.Google Scholar
  19. 19.
    Skrobot OA, O’Brien J, Black S, et al. The vascular impairment of cognition classification consensus study. Alzheimers Dement. 2017;13(6):624–33.PubMedCrossRefGoogle Scholar
  20. 20.
    Gorelick PB, Furie KL, Iadecola C, et al. Defining optimal brain health in adults: a presidential advisory from the American Heart Association/American Stroke Association. Stroke. 2017;48(10):e284–303.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment—a critical update. Front Aging Neurosci. 2013;5:17.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822–38.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet. 2016;388(10043):505–17.PubMedCrossRefGoogle Scholar
  24. 24.
    Maillard P, Mitchell GF, Himali JJ, et al. Effects of arterial stiffness on brain integrity in young adults from the Framingham Heart Study. Stroke. 2016;47(4):1030–6.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Jellinger KA. Clinicopathological analysis of dementia disorders in the elderly—an update. J Alzheimers Dis. 2006;9(3 Suppl):61–70.PubMedCrossRefGoogle Scholar
  26. 26.
    Testai FD, Gorelick PB. Vascular cognitive impairment and Alzheimer disease: are these disorders linked to hypertension and other cardiovascular risk factors? In: Aiyagari V, Gorelick PB, editors. Hypertension and stroke. 2nd ed. New York: Humana Press; 2016. p. 261–84.CrossRefGoogle Scholar
  27. 27.
    Kisler K, Nelson AR, Montagne A, et al. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18(7):419–34.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Tarasoff-Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol. 2015;11(8):457–70.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352(9137):1347–51.PubMedCrossRefGoogle Scholar
  30. 30.
    Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163(9):1069–75.PubMedCrossRefGoogle Scholar
  31. 31.
    Iadecola C, Yaffe K, Biller J, et al. Impact of hypertension on cognitive function: a scientific statement from the American Heart Association. Hypertension. 2016;68(6):e67–94.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011;10(11):969–77.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Cukierman-Yaffe T, Bosch J, Diaz R, et al. Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. Lancet Diabetes Endocrinol. 2014;2(7):562–72.PubMedCrossRefGoogle Scholar
  34. 34.
    Tuligenga RH. Intensive glycaemic control and cognitive decline in patients with type 2 diabetes: a meta-analysis. Endocr Connect. 2015;4(2):R16–24.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Areosa Sastre A, Vernooij RW, Gonzalez-Colaco Harmand M, et al. Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev. 2017;6:CD003804.PubMedGoogle Scholar
  36. 36.
    Reis JP, Loria CM, Launer LJ, et al. Cardiovascular health through young adulthood and cognitive functioning in midlife. Ann Neurol. 2013;73(2):170–9.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Andrieu S, Guyonnet S, Coley N, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16(5):377–89.PubMedCrossRefGoogle Scholar
  38. 38.
    Moll van Charante EP, Richard E, Eurelings LS, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet. 2016;388(10046):797–805.PubMedCrossRefGoogle Scholar
  39. 39.
    Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–63.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Maillard P, Mitchell GF, Himali JJ, et al. Aortic stiffness, increased white matter free water, and altered microstructural integrity: a continuum of injury. Stroke. 2017;48(6):1567–73.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Singapore 2020

Authors and Affiliations

  1. 1.Department of Neurology and RehabilitationUniversity of Illinois at ChicagoChicagoUSA
  2. 2.Davee Department of NeurologyNorthwestern University Feinberg School of MedicineChicagoUSA
  3. 3.Department of Translational NeuroscienceMichigan State University College of Human MedicineGrand RapidsUSA

Personalised recommendations